Background: Valacyclovir is an oral prodrug of acyclovir. It has a bioavailability 35 times greater than that of oral acyclovir. Moreover the convenient dose schedule as well as quicker cesation of post herpetic neuralgia makes valacyclovir more effacious than acyclovir in treating herpes zoster. So, the present study was planned to compare the efficacy and safety of oral valacyclovir over oral acyclovir in the treatment of herpes zoster.
Methods: This was a clinical trial conducted in the outpatient department of Dermatology and Venereology at Shaheed Suhrawardy Medical College and Hospital, Dhaka between the period of April 2016 to September 2016. Sixty patients were selected according to the inclusion and exclusion criteria. All the patients were randomized into two groups. Group A as Valacyclovir (n=30) and group B as Acyclovir (n=30). Complete history was taken from the patient. Thorough clinical examination was done. Relevant investigations report was collected. All the informations were recorded in the fixed questionnaire. Collected data was classified, edited, coded and entered into the computer for statistical analysis by using SPSS-19.
Result: Mean age was found 38.93±8.29 years in group A and 41.36±8.36 years in group B. 17 (56.7%) patients were male in group A and 16 (53.3%) in group B. Majority (56.7%) patients were thoracic in group A and group B respectively. In group A erythema, maculopapular rash, vesicle, bullae and crusting were present 29 (96.7%) cases, 28 (93.3%) cases, 22 (73.3%) cases, 22 (73.3%) cases and 14 (46.7%) cases respectively. In group B erythema, maculopapular rash, vesicle, bullae and crusting were present in 30 (100.0%) cases, 30 (100.0%) cases, 29 (96.7%) cases, 25(83.3%) cases and 17 (56.7%) cases respectively. Incidence of postherpetic neuralgia was found in 21 (70.0%) cases in group A and in 25 (83.3%) cases in group B. After 7 days treatment with valacyclovir in group A and acyclovir in group B, it was observed that symptoms and signs were reduced in both groups but more effectively in group A though the differences between the groups were statistically non-significant. However, it was observed that the patients of both groups showed similar remission pattern on 15th and 29th day. In baseline, mean pain scoring were 6.26±2.22 and 6.53±1.81 minutes in group A and group B respectively. At 3rd days, mean pain scoring was found 5.47±1.85 minutes in group A and 5.93±1.72 minutes in group B. At 8th days, mean pain scoring was found 4.23±1.50 minutes in group A and 5.13±1.45 minutes in group B. At 15th days, mean pain scoring was found 2.00±1.22 minutes in group A and 3.25±1.07 minutes in group B. At 22th days, mean pain scoring was found 0.76±0.74 minutes in group A and 1.75±0.95 minutes in group B. At 29th days, mean pain scoring was found 0.00±0.00 minutes in group A and 1.17±0.57 minutes in group B. The mean score at 8th, 15th, 22th days were statistically significant (p<0.05) between two groups.
Conclusion: It can be concluded that administration of valacyclovir three times daily was an effective and safe treatment for acute herpes zoster. Treatment with valacyclovir has the benefits of rapid resolution of skin lesions, zoster associated pain, post herpetic neuralgia compared to acyclovir and valacyclovir has the convenience three times daily dosing, thereby ensuring better patient compliance, which makes this regimen an excellent choice for treatment of herpes zoster.